4/5
10:26 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
4/4
12:33 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Citigroup Inc. from $26.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Citigroup Inc. from $26.00 to $30.00. They now have a "buy" rating on the stock.
3/22
02:32 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
3/22
01:46 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Wells Fargo & Company from $34.00 to $35.00. They now have an "overweight" rating on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Wells Fargo & Company from $34.00 to $35.00. They now have an "overweight" rating on the stock.
3/22
11:19 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
3/21
07:17 am
caba
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/21
07:00 am
caba
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/20
07:12 am
caba
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis [Yahoo! Finance]
Low
Report
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis [Yahoo! Finance]
3/20
07:00 am
caba
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
Low
Report
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
2/27
10:29 am
caba
Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 [Yahoo! Finance]
Low
Report
Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 [Yahoo! Finance]
2/27
08:00 am
caba
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
Low
Report
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
2/5
07:16 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $36.00 price target on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $36.00 price target on the stock.
2/1
04:33 pm
caba
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis [Yahoo! Finance]
Medium
Report
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis [Yahoo! Finance]
2/1
04:30 pm
caba
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
Medium
Report
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
1/31
08:00 am
caba
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Medium
Report
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference